Table 3.

Clinical relevance of TIM-3 and TIGIT expressions on tumor cells.

	TIM-3 tumor			TIGIT tumor
Clinicopathological characteristics	Low	High	P	Low		High	P
Gender
Male	65	19	0.547	73		12	0.201
Female	49	18		57		16
Age, years
≤59	61	20	0.954	68		13	0.572
>59	53	17		62		15
Ann-Arbor stage
I and II	27	9	0.952	33		4	0.177
III and IV	74	24		80		21
IPI
Low risk (0-1 score)	35	18	0.213	43		12	0.482
Medium risk (2-3 score)	66	17		72		13
High risk (4-5 score)	5	2		5		2
Performance state
≤2 score	98	36	0.296	112		27	0.196
>2 score	8	1		7		0
LDH, u/l
≤250	56	15	0.908	68		8	0.230
>250	39	11		41		9
B symptom
Yes	22	15	0.019*	32		8	0.956
No	77	20		78		19
Location
Extranodular	69	20	0.682	80		15	0.578
Intranodular	41	14		46		11
Diameter, cm
≤5	81	27	0.935	91		21	0.861
>5	28	9		33		7
Subtypes
GCB	30	10	0.907	30		10	0.186
Non-GCB	82	26		97		18
Extranodal sites
≤2	82	28	0.696	92		22	0.425
>2	28	8		32		5
Bone Mallow Needle Biopsy
Yes	16	2	0.166	18		2	0.230
No	79	28		87		24
R-CHOP treatment
Yes	48	19	0.340	57		12	0.825
No	52	14		56		13